GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sandoz Group SDZ.SW · CHF

Health Care · Pharmaceuticals · SIX · 🇨🇭 Switzerland

Compare

84.46

+0.81%

Close of 9 Nov 2026, in CHF

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$11.16bn

FY2020FY2025

Net income

$957.5m

FY2020FY2025

Free cash flow

$810.0m

FY2020FY2025

Shareholders' equity

$9.38bn

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Revenue$11.16bn$11.08bn$12.13bn$8.86bn$8.83bn$8.55bn
Gross profit$5.28bn$5.24bn$5.55bn$4.15bn$4.20bn$3.95bn
Research and development$1.10bn$1.16bn$1.13bn$795.6m$831.1m$772.9m
Operating income$1.43bn$1.65bn$455.7m$87.0m$1.27bn$710.0m
Net income$957.5m$1.2m$93.6m−$22,861$828.4m$409.0m
Diluted earnings per share2.190.000.22-0.001.920.95

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$22.03bn$24.19bn$23.61bn$100,000$15.98bn$15.86bn
Cash and short-term investments$1.74bn$1.45bn$1.13bn$100,000$36.4m$34.5m
Total liabilities$12.65bn$14.27bn$13.09bn$22,861$8.55bn$9.04bn
Debt$5.68bn$5.90bn$5.53bn$309.0m$284.3m$298.8m
Shareholders' equity$9.38bn$9.92bn$8.84bn$77,139$7.43bn$6.82bn
Shares outstanding438m434m430m430m431m431m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations$1.59bn$797.1m$395.3m$1.17bn$1.24bn$1.03bn
Capital spending−$784.0m−$724.2m−$690.1m−$407.8m−$382.2m−$309.7m
Free cash flow$810.0m$72.9m−$294.8m$760.2m$855.8m$720.9m
Dividends paid−$315.0m−$261.2m————

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue$5.63bn$5.91bn$5.26bn$4.93bn$6.15bn$2.53bn$2.12bn$2.52bn
Gross profit$2.63bn$2.86bn$2.41bn$2.35bn$2.89bn$1.19bn$921.0m$1.09bn
Operating income$793.3m$1.03bn$602.0m$1.25bn$403.4m$166.0m−$36.6m−$43.5m
Net income$106.6m$541.7m$377.0m−$182.3m$182.3m$75.0m−$66.4m−$79.0m
Diluted earnings per share0.241.240.86-0.420.420.17-0.15-0.18
Cash from operations$851.0m$1.07bn$523.0m$518.0m$278.0m$114.0m$277.0m$138.0m
Capital spending−$260.0m−$581.0m−$203.0m−$523.0m−$200.0m−$82.0m−$209.0m−$104.0m
Free cash flow$591.0m$490.0m$320.0m−$5.0m$78.0m$32.0m$68.0m$34.0m
Total assets$22.86bn$22.03bn$21.61bn$24.19bn$23.47bn$19.32bn$19.43bn$19.43bn
Cash and short-term investments$1.25bn$1.74bn$1.39bn$1.45bn$851.8m$701.0m$1.11bn$1.11bn
Debt$5.92bn$5.69bn$5.69bn$5.90bn$5.33bn$295.0m$284.0m$284.0m
Shareholders' equity$9.02bn$9.38bn$8.82bn$9.92bn$10.17bn$8.37bn$8.64bn$8.64bn

Financial ratios

Data as of 20 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin47.4%47.3%45.7%46.9%47.5%46.2%
Operating margin12.8%14.9%3.8%1.0%14.4%8.3%
Net margin8.6%0.0%0.8%-0.0%9.4%4.8%
Return on equity10.2%0.0%1.1%-29.6%11.2%6.0%
Return on assets4.3%0.0%0.4%-22.9%5.2%2.6%
Free cash flow yield7.9%4.2%3.0%5.3%5.5%4.5%
Revenue growth22.3%-8.6%12.6%0.3%3.3%—
Earnings growth95648.4%-98.7%-336918.2%-100.0%102.5%—
Current ratio1.18x1.24x1.12x4.37x0.67x0.62x
Debt to equity0.57x0.56x0.59x2979.60x0.02x0.03x
Equity ratio42.6%41.0%37.4%77.1%46.5%43.0%
Interest coverage6.48x5.78x1.86x1.03x20.76x10.09x
R&D as a share of sales9.9%10.5%9.3%9.0%9.4%9.0%
Buybacks as a share of market value-0.8%-1.0%0.0%0.3%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.0%5.5%—
Operating income154.0%15.0%—
Net income—18.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin47.3%46.8%46.8%—
Operating margin13.8%8.4%9.2%—
Net margin4.3%2.4%3.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings33.5—157.6
Price to sales2.91.91.2

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 17 Apr 2025.

FY2025FY2024
Paid in the year0.600.45

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.